Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

Summary

To investigate whether a year of rasagiline may reduce the progression from idiopathic REM sleep behavior disorder (RBD) to Parkinson's disease (PD).

Conditions

• REM Sleep Behavior Disorder
• Parkinson Disease
• Synucleinopathies

Interventions

DRUG

Rasagiline

1 mg rasagiline

Sponsors & Collaborators

• Beijing Tiantan Hospital

  collaborator OTHER

• Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• Jiangsu Province Nanjing Brain Hospital

  collaborator OTHER

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• Huashan Hospital

  collaborator OTHER

• Second Affiliated Hospital of Soochow University

  collaborator OTHER

• Guizhou Medical University

  collaborator OTHER

• The First Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Sir Run Run Shaw Hospital

  collaborator OTHER

• The Affiliated Hospital of Hangzhou Normal University

  collaborator OTHER

• The First Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Fujian Medical University Union Hospital

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Principal Investigators

• Baorong Zhang, MD · Second Affiliated Hospital, Zhejiang University, China

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

30 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-01-01

Primary Completion

2025-12-31

Completion

2026-12-31